- Contact Us Now: (202) 589-1834 Tap Here to Call Us
FTC Forces Abandonment of Alcon’s Acquisition of LENSAR, Preserving Competition in Cataract Laser Systems
On March 16, 2026, Alcon, Inc. and LENSAR, Inc. mutually agreed to terminate their merger agreement after the Federal Trade Commission indicated it would seek to block the transaction. The proposed deal, announced in March 2025 and valued at approximately $356 million upfront (with potential milestones bringing the total to roughly $430 million), would have combined the two most significant competitors in the market for femtosecond laser-assisted cataract surgery (FLACS) systems. The parties abandoned the combination rather than face a full antitrust challenge in court.
The Deal and Competitive Concerns
Alcon is a global eye-care company and a leading supplier of cataract-surgery technology, including its LenSx laser system. LENSAR manufactures the ALLY Robotic Cataract Laser Treatment System, along with related software and earlier-generation laser platforms. The FTC’s Bureau of Competition, through its American Competition Enforcement (ACE) Division, concluded that the merger would eliminate the intense head-to-head rivalry between the two firms.
Bureau of Competition Director Daniel Guarnera stated that Alcon and LENSAR were “locked in a price war that had already benefited doctors offering FLACS-assisted cataract procedures, as well as their patients,” and that the competition had also driven innovation in the FLACS market. Combining the two most significant players, he said, would have reduced price competition, slowed technological progress, and harmed surgeons and the millions of American patients who undergo cataract procedures. The FTC also noted partnership with the Florida Attorney General’s Office during the investigation.
Termination and Company Statements
Alcon and LENSAR announced the mutual termination on March 16, 2026. Alcon’s CEO, David J. Endicott, said the company continued to believe the acquisition would have enhanced FLACS innovation and competition, but that “the delay and associated costs of this extended regulatory review, which began nearly a year ago, has rendered the transaction unattractive to pursue further in light of the Federal Trade Commission’s opposition.” LENSAR’s CEO, Nick Curtis, expressed disappointment with the FTC’s intention to challenge the deal but affirmed the company’s commitment to advancing its ALLY system. Under the termination agreement, LENSAR retained a $10 million deposit paid by Alcon. The original merger agreement had an outside date of April 23, 2026, with a possible extension to July 23; the parties concluded that necessary U.S. regulatory approvals were unlikely to be obtained in time.
Implications
The abandonment illustrates the FTC’s willingness to challenge horizontal combinations of close rivals in specialized medical-device markets, particularly where ongoing price competition and innovation rivalry can be documented. Director Guarnera emphasized that competitors “simply cannot attempt to buy out rivals to get out from the heat of pricing and innovation competition” and credited the investigation with producing evidence of consumer harm sufficient to cause the parties to withdraw rather than litigate. The outcome preserves independent competition between Alcon’s and LENSAR’s laser systems for the benefit of surgeons and patients, while also supporting domestic manufacturing activity associated with the products.
For medical-device companies evaluating acquisitions of direct rivals in concentrated segments, the Alcon-LENSAR episode underscores that prolonged regulatory scrutiny, combined with strong evidence of head-to-head competition, can make a transaction untenable even when the parties remain willing to close. The FTC’s public statement frames the result as a successful enforcement action that protects price competition, innovation, and American manufacturing jobs in the FLACS market.
Andre Barlow
abarlow@dbmlawgroup.com






